Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the sulfanilide class of organic compounds. It is characterized by a benzoic acid core substituted with a bromo group and a (4-chlorophenyl)sulfonamide moiety. The compound acts as an inhibitor of methionine aminopeptidase 2 (MetAP2), an enzyme involved in protein processing and angiogenesis. While it has been studied experimentally for its biochemical properties and potential biological activity related to MetAP2 inhibition—an approach explored in antiangiogenic cancer therapy—it is not approved for clinical use or any therapeutic indication[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 5-bromo-2-{[(4-chlorophenyl)sulfonyl]amino}benzoic acid.